Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease-Reference-Cited by-同舟云学术

Neutrophil gelatinase-associated lipocalin as a risk marker in cardiovascular disease

Published:2017-06-23 Issue:1 Volume:56 Page:5-18
ISSN:1437-4331
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Sivalingam Zenthuja¹,Larsen Sanne Bøjet¹,Grove Erik Lerkevang¹²,Hvas Anne-Mette²³,Kristensen Steen Dalby¹²,Magnusson Nils Erik⁴

Affiliation:

1. Department of Cardiology , Aarhus University Hospital , Aarhus , Denmark

2. Faculty of Health, Institute of Clinical Medicine , Aarhus University , Aarhus , Denmark

3. Department of Clinical Biochemistry , Aarhus University Hospital , Aarhus , Denmark

4. The Medical Research Laboratories , Department of Clinical Medicine , Faculty of Health Sciences , Aarhus University , Nørrebrogade 44, 8000 Aarhus C , Denmark

Abstract

Abstract Neutrophil gelatinase-associated lipocalin (NGAL) is a promising diagnostic biomarker of early acute kidney injury. Increasing evidence suggests that NGAL may also be involved in inflammatory processes in cardiovascular disease. NGAL modulates the enzymatic activity of matrix metalloproteinase-9 (MMP-9), which is an important mediator of plaque instability in atherosclerosis. The complex formation between NGAL and MMP-9 therefore suggests that NGAL might play a role in progression of atherothrombotic disease. This review summarises current data on NGAL in atherosclerosis, acute myocardial infarction, and heart failure.

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry (medical),Clinical Biochemistry,General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2017-0120/pdf

Reference60 articles.

1. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2016;352:1685–95.

2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011;473:317–25.

3. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387–97.

4. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, et al. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation 2007;115:1528–36.

5. Hemdahl AL, Gabrielsen A, Zhu C, Eriksson P, Hedin U, Kastrup J, et al. Expression of neutrophil gelatinase-associated lipocalin in atherosclerosis and myocardial infarction. Arterioscler Thromb Vasc Biol 2006;26:136–42.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early neutrophil gelatinase‐associated lipocalin (NGAL) measurement could rule out future acute kidney injury in patients with acute coronary syndrome—Prospective observational study;Health Science Reports;2024-07

2. Clinical Impacts of Urinary Neutrophil Gelatinase-Associated Lipocalin in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention;Circulation Journal;2024-05-24

3. Biomarkers in assessing the vulnerability of atherosclerotic plaques: a narrative review;Rational Pharmacotherapy in Cardiology;2023-07-27

4. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL);International Journal of Molecular Sciences;2023-06-21

5. NETosis in Acute Thrombotic Disorders;Seminars in Thrombosis and Hemostasis;2023-06-12